The pharmaceutical sector represents a significant part of the global healthcare market, but which companies are the largest by value?
We’ve reviewed the biggest publicly listed pharmaceutical companies by market capitalisation – calculated as a company’s share price multiplied by the total number of its outstanding shares – as of 5 May 2026.
Our rankings list the top pharmaceutical companies worldwide by market capitalisation as of 5 May 2026. Each company’s market cap is shown in US dollars (USD), together with its latest share price and main country of listing.
| Rank | Company | Market cap (USD) | Share price (USD) | Country |
|---|---|---|---|---|
| 1 | Eli Lilly | $863.1bn | $967.93 | USA |
| 2 | Johnson & Johnson | $539.7bn | $224.20 | USA |
| 3 | AbbVie | $368.2bn | $208.16 | USA |
| 4 | Roche | $332.6bn | $418.06 | Switzerland |
| 5 | AstraZeneca | $284.4bn | $183.46 | UK |
| 6 | Merck | $279.4bn | $113.11 | USA |
| 7 | Novartis | $275.9bn | $144.62 | Switzerland |
| 8 | Novo Nordisk | $196.8bn | $44.39 | Denmark |
| 9 | Amgen | $174.9bn | $323.85 | USA |
| 10 | Gilead Sciences | $164.7bn | $132.69 | USA |
| 11 | Pfizer | $149.6bn | $26.30 | USA |
| 12 | Bristol-Myers Squibb | $117.2bn | $57.38 | USA |
| 13 | Vertex Pharmaceuticals | $109.3bn | $429.85 | USA |
| 14 | CVS Health | $105.1bn | $82.01 | USA |
| 15 | Sanofi | $103.9bn | $43.35 | France |
The information on this page is based on data from public company disclosures, including SEC filings and EDGAR. It is provided for informational purposes only and does not constitute investment advice or a recommendation to trade. While considered accurate on the dates stated, the figures may be updated without notice.
A pharmaceutical company's market capitalisation reflects what investors expect from its future revenue. Those expectations are shaped by factors such as pipeline strength, patent protection, treatment focus and commercial scale. Companies with exposure to high-growth areas, including oncology, immunology and metabolic disease, may attract higher valuations, although this can vary with market conditions and company-specific factors. Market cap can also move quickly after clinical trial results, regulatory decisions or earnings updates, making valuations sensitive to new information. Biologics have become an important source of sector growth, partly because they can be harder for generic competitors to replicate than traditional small-molecule drugs – biosimilar manufacturers cannot simply copy a recipe and must instead reverse-engineer the product and develop their own proprietary manufacturing process to produce a molecule that is demonstrably 'highly similar' to the original (Drug Patent Watch, 7 January 2026). Wider economic factors also play a role. Interest rates, currency moves and the strength of the US dollar can affect valuations, especially for non-US-listed companies whose market caps are reported in USD.
GLP-1 receptor agonists, first developed for type 2 diabetes and now widely used for obesity, have become one of the sector's most commercially significant drug classes. Obesity assets now account for about 25% of forecast sales in the global late-stage pharmaceutical pipeline, ahead of oncology's 20% share, according to Deloitte research (Medpath, 4 May 2026). The global GLP-1 analogue market was valued at $54.8bn in 2024 and is growing at a compound annual growth rate of 30.6% (BCC Research, 30 January 2026). That growth has directed capital towards companies with GLP-1 exposure and shifted the sector's market cap mix. It also creates concentration risk. Safety findings, reimbursement decisions, supply constraints or new competitors could all affect future revenue expectations and, in turn, company valuations.
The patent cliff describes the point at which exclusivity on high-revenue drugs expires and generic or biosimilar competition enters the market. When that happens, revenue from affected products can fall sharply, which may put pressure on earnings and valuations. Industry analysts estimate that between 2025 and 2030, about $236bn in annual pharmaceutical sales are at risk from patent expiries (LinkedIn/Raman Goel, 12 August 2025). Several widely prescribed drugs in areas such as immunology, cardiology and primary care are expected to lose protection during this period. Companies that rely on a small number of products for most of their revenue can face greater exposure than those with broader portfolios. Analysts therefore tend to focus on pipeline depth, diversification and the ability to replace expiring sales with newly approved medicines when assessing longer-term valuation resilience.
Regulatory decisions can be important valuation events for pharmaceutical companies. An approval can expand a company's revenue outlook and support a higher market capitalisation, while a rejection or clinical setback can reduce expectations and weigh on the share price. The FDA approved 46 new drugs in 2025, above the long-run historic average of 36 per year since 1993 (Nature, 8 January 2026; FDA, 23 April 2026). In Q1 2026, further novel approvals were granted across several therapeutic areas, extending an active regulatory period. Outside the US, decisions from the European Medicines Agency (EMA) and other regulators can also affect valuations, especially for companies with significant non-US revenue. Investors often follow late-stage clinical trial data, filing dates and review timelines because they can provide early signals about potential future sales.
Learn more about market capitalisation.
Pharmaceutical investing means gaining exposure to companies focused on drug discovery, development and commercialisation. This can involve buying shares directly or trading derivatives such as contracts for difference (CFDs), which allow speculation on price movements without owning the underlying asset. CFDs are traded on margin – leverage amplifies both your profits and your losses. The pharma sector is sensitive to clinical trial results, with early-stage biotechnology companies often experiencing greater price volatility than larger pharmaceutical firms. Share prices may move in response to trial outcomes, regulatory approvals, patent expirations and wider market sentiment.
To trade pharmaceutical share CFDs, you’ll need to open and verify an account with a regulated CFD provider. Once approved, you can deposit funds and access the trading platform. CFD trading is subject to local rules, including leverage limits. Many retail CFD accounts lose money. It’s important to understand the risks, review company pipelines, and practise using a demo account before committing real funds.
Start by researching each company’s pipeline, patent timelines and financial position. The sector carries risks including clinical trial failures, regulatory delays and patent cliff events – when protection ends and revenues can fall sharply as generics enter the market. New traders may find simple strategies more manageable while learning. Risk management tools such as stop-loss orders can help, but stop-loss orders are not guaranteed. Guaranteed stop loss orders (GSLOs) incur a fee if activated. CFD trading remains high risk and rapid losses may occur due to leverage. Never trade with money you can’t afford to lose.
Great customer service I got to say that. They helped get my account back very fast, after i logged myself out by losing my old email, it was so fast you wouldn’t believe it thank you once again.
Everything worked as expected from the 1 day. I didn’t have to search how to use the platform, it’s intuitive. The support chat was there when I had a tiny issue.
Capital.com has been great for both learning and trading. The app is clean, fast, and packed with useful tools. Customer support has been solid too. Definitely recommended for beginners and active traders alike.
I trade every day and Capital is my beloved home. I also create music and you can always feel when something has been created from the heart. Capital has soul!
I would like to express a huge thank you to Evgeniya Logvinovich, customer service manager. For your attention and heartfelt attitude to your clients.❤️
I am extremely happy with this broker. Great spreads, good selection of instruments, well coded toolbox.
Love the TV integration. Makes traders life smooth and comfortable.
I trade every day and Capital is my beloved home. I also create music and you can always feel when something has been created from the heart. Capital has soul!
I’d been paper trading for 2yrs now, went live and this platform is easy for beginners to understand and navigate all important tools to execute all that I learned. Earning now!
This application is perfect.. simple, easy to use, run smoothly and fast and it has an accurate graphics.. be careful to use only one credit card and one bank account to prevent any withdrawal problem.. overnight fees and spread variation will be repaid for you by the next month.. I used many application but this is the best one
User friendly app & interface and good support team. Funds transfer ease & Leverage is an advantage but crypto is highly risky be responsible of your loss limits and risks appetite.
Capital is really great to be used on start, also beginner friendly broker! Great costumer support and it is quick!
Showing our 4 & 5 star reviews. The specific details of the user have been intentionally anonymised to safeguard their privacy pursuant to GDPR requirements.
Why choose Capital.com? Our numbers speak for themselves
Capital.com Group
Ratings and Reviews
Ratings and Reviews